Skip to Content

Umeclidinium / Vilanterol Dosage

Medically reviewed on December 26, 2017.

Applies to the following strengths: 62.5 mcg-25 mcg/inh

Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance

One inhalation (umeclidinium 62.5 mcg-vilanterol 25 mcg) orally once a day
Maximum dose: One inhalation every 24 hours

Use: Long term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.


-Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including vilanterol, one of the active ingredients of this drug.
-The safety and efficacy of this drug in patients with asthma have not been established, and it is not indicated for the treatment of asthma.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for dosing related precautions.


Data not available

Other Comments

Administration advice:
-This drug should be taken at the same time every day.
-This drug should be used by orally inhaled route only.
-Discard 6 weeks after opening the foil tray or when the counter reads zero, whichever comes first.

Storage requirements:
-Store in the unopened protective foil tray in a dry place away from direct heat or sunlight, and only open when ready to use.

Reconstitution/preparation techniques: The manufacturer's product information should be consulted.

-This drug should not be used to relieve acute symptoms of COPD.
-For the treatment of acute symptoms use a rescue inhaler (i.e., albuterol).

Patient advice:
-Patients should seek medical attention immediately if their COPD symptoms get worse, if they need more inhalations than usual of their rescue inhaler, if they develop signs and symptoms of narrow-angle glaucoma and/or urinary retention.
-Patients should not stop therapy with this drug without physician/provider guidance since symptoms may recur after discontinuation.
-Patients should not use other medicines containing a long-acting beta2 agonists (LABA).
-Patients should not use more than the recommended once daily dose of this drug.
-If short-acting beta2 agonists have been taken on a regular basis, discontinue the regular use of these products and use them only for the symptomatic relief of acute symptoms.
-Patients should report immediately any signs or symptoms of palpitations, chest pain, rapid heart rate, tremor, or nervousness.
-Discontinue this drug if paradoxical bronchospasm occurs.
-Write the date you open the tray on the label on the inhaler.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.